Banco Santander S.A. Has $968,000 Stock Position in Haleon plc (NYSE:HLN)

Banco Santander S.A. decreased its stake in Haleon plc (NYSE:HLN) by 37.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 114,040 shares of the company’s stock after selling 67,210 shares during the period. Banco Santander S.A.’s holdings in Haleon were worth $968,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Clearbridge Investments LLC grew its stake in shares of Haleon by 2.4% in the fourth quarter. Clearbridge Investments LLC now owns 26,581,902 shares of the company’s stock worth $218,769,000 after acquiring an additional 612,400 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Haleon by 164.6% in the fourth quarter. Wellington Management Group LLP now owns 13,542,346 shares of the company’s stock worth $111,454,000 after acquiring an additional 8,423,475 shares during the last quarter. Douglas Lane & Associates LLC grew its stake in shares of Haleon by 2.1% in the first quarter. Douglas Lane & Associates LLC now owns 8,401,876 shares of the company’s stock worth $71,332,000 after acquiring an additional 175,082 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Haleon by 19.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 4,813,997 shares of the company’s stock worth $39,619,000 after acquiring an additional 772,829 shares during the last quarter. Finally, Martin Investment Management LLC grew its stake in shares of Haleon by 12,018.4% in the first quarter. Martin Investment Management LLC now owns 4,463,205 shares of the company’s stock worth $37,893,000 after acquiring an additional 4,426,375 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Price Performance

Haleon stock remained flat at $8.91 on Friday. 1,704,176 shares of the company’s stock traded hands, compared to its average volume of 3,357,199. The stock has a market capitalization of $40.68 billion, a price-to-earnings ratio of 29.70, a P/E/G ratio of 2.56 and a beta of 0.24. The company has a current ratio of 1.04, a quick ratio of 0.73 and a debt-to-equity ratio of 0.53. The firm has a 50 day simple moving average of $8.51 and a two-hundred day simple moving average of $8.39. Haleon plc has a 12-month low of $7.70 and a 12-month high of $9.00.

Haleon (NYSE:HLN) last announced its quarterly earnings results on Wednesday, May 1st. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.01. The firm had revenue of $3.70 billion for the quarter, compared to analyst estimates of $3.71 billion. Haleon had a net margin of 9.68% and a return on equity of 13.17%. Analysts anticipate that Haleon plc will post 0.47 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. HSBC started coverage on shares of Haleon in a research note on Wednesday, April 17th. They issued a “buy” rating on the stock. Argus reissued a “buy” rating on shares of Haleon in a report on Tuesday, March 26th. Finally, Berenberg Bank assumed coverage on shares of Haleon in a report on Wednesday, June 5th. They issued a “buy” rating on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.